Elevance Health (ELV): Bridging the Gap between Care and Coverage

Hotchkis & Wiley, an investment management firm, released its second-quarter 2026 investor letter, highlighting Elevance Health (NYSE:ELV) as a notable performer among the fund's holdings. The Russell 1000 Value Index saw a robust 13.9% increase in the quarter, although individual stocks generally lagged behind. AI-related sectors and semiconductor stocks experienced significant gains, contributing to the speculative rally in equity markets.

The letter noted that while high-beta and low-volatility stocks showed strong performance, momentum stocks outperformed the market significantly.

Despite the enthusiasm for AI investments, the letter raised concerns over inflated valuations akin to those seen during the dot-com era. The fund's cautious stance suggests that the market may revert to valuations grounded in fundamental economic realities, with the selected investments believed to be better prepared for such a shift.

Hotchkis & Wiley provided a positive rating on Elevance Health's Q2 2026 performance, noting that the company's shares rose during the quarter after reporting quarterly earnings that surpassed consensus estimates. This was further bolstered by news of the U.S. agreeing to raise 2027 payments for private Medicare Advantage plans above the initial proposal.

The company, being the second-largest health insurer and one of the largest commercial insurers in the U.S., is currently priced at a discount to the market, driven by skepticism regarding margins and growth.

The letter acknowledged Elevance Health's superior growth and cash returns to shareholders, despite the company being on the fund's list of 40 most popular stocks among hedge funds. Nevertheless, the fund maintained that certain AI stocks offer greater upside potential and less downside risk.